SPC
VRTX icon

Sigma Planning Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Sigma Planning Corp’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$513K Sell
1,033
-29
-3% -$12.9K 0.01% 905
2026
Q1 		$474K Sell
1,062
-624
-37% -$291K 0.01% 858
2025
Q4 		$764K Buy
1,686
+54
+3% +$23.3K 0.02% 629
2025
Q3 		$639K Sell
1,632
-648
-28% -$271K 0.02% 712
2025
Q2 		$1.01M Sell
2,280
-34
-1% -$15.7K 0.03% 496
2025
Q1 		$1.12M Sell
2,314
-17
-0.7% -$7.92K 0.04% 457
2024
Q4 		$939K Sell
2,331
-415
-15% -$192K 0.03% 510
2024
Q3 		$1.28M Sell
2,746
-261
-9% -$125K 0.04% 416
2024
Q2 		$1.41M Buy
3,007
+14
+0.5% +$6.08K 0.04% 375
2024
Q1 		$1.25M Buy
2,993
+1,212
+68% +$512K 0.04% 436
2023
Q4 		$724K Sell
1,781
-1,061
-37% -$392K 0.06% 339
2023
Q3 		$988K Buy
2,842
+80
+3% +$28K 0.04% 471
2023
Q2 		$972K Buy
2,762
+10
+0.4% +$3.37K 0.03% 464
2023
Q1 		$867K Sell
2,752
-412
-13% -$124K 0.03% 569
2022
Q4 		$914K Buy
3,164
+44
+1% +$13.4K 0.03% 519
2022
Q3 		$903K Buy
3,120
+1,082
+53% +$311K 0.03% 494
2022
Q2 		$574K Buy
2,038
+535
+36% +$143K 0.02% 700
2022
Q1 		$392K Sell
1,503
-112
-7% -$26.6K 0.01% 942
2021
Q4 		$355K Sell
1,615
-1,193
-42% -$232K 0.01% 1000
2021
Q3 		$509K Buy
2,808
+1,201
+75% +$234K 0.02% 808
2021
Q2 		$324K Buy
1,607
+390
+32% +$81.6K 0.01% 1042
2021
Q1 		$262K Buy
1,217
+22
+2% +$4.83K 0.01% 1064
2020
Q4 		$282K Buy
+1,195
New +$274K 0.01% 934
2020
Q3 		– Sell
-9,006
Closed -$2.62M – 1168
2020
Q2 		$2.62M Buy
+9,006
New +$2.44M 0.11% 183
2020
Q1 		– Sell
-1,104
Closed -$242K – 1116
2019
Q4 		$242K Buy
+1,104
New +$223K 0.01% 891
2015
Q1 		– Sell
-8,483
Closed -$1.01M – 790
2014
Q4 		$1.01M Buy
+8,483
New +$955K 0.13% 181

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sigma Planning Corp's VRTX Position: Q2 2026 in Review

Sigma Planning Corp reduced its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q2 2026, selling an estimated $12.9K and leaving 1,033 shares worth $513K. The position accounts for 0.01% of the portfolio, ranked #905.

Sigma Planning Corp first reported a position in VRTX in Q4 2014 and has held it in 26 quarters since. The position peaked at $2.62M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sigma Planning Corp held 1,033 shares of Vertex Pharmaceuticals worth $513K as of Q2 2026.
  • Sigma Planning Corp sold 29 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
  • Vertex Pharmaceuticals made up 0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #905 holding.
  • Sigma Planning Corp first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 26 quarters since.
  • Sigma Planning Corp's Vertex Pharmaceuticals position peaked at $2.62M in Q2 2020.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.